Founded in 1988 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is a leading provider of point-of-care diagnostic and specimen collection devices under the NASDAQ ticker OSUR. The company's core product lines include the OraQuick HIV and HCV rapid antibody tests, which are used by healthcare providers, public health programs and consumers for early detection of infection. OraSure has expanded its point-of-care franchise to encompass other infectious diseases, including COVID-19 rapid antigen and molecular assays, as well as tuberculosis screening solutions.
In addition to its diagnostic offerings, OraSure holds a prominent position in the specimen collection market. The company’s saliva-based oral fluid collection devices, syphilis blood testing kits and stabilization systems for DNA and RNA collection support a wide range of applications—from forensic testing and consumer genomics to pharmaceutical research and microbiome analysis. These devices streamline the sample-collection process by enabling noninvasive, self-collected specimens, facilitating large-scale screening and decentralized testing models.
OraSure Technologies has built a global distribution network spanning more than 100 countries, with sales, R&D and manufacturing facilities in the United States, Europe and Asia. Over the years, the company has forged strategic partnerships with public health agencies, academic institutions and major diagnostic firms to accelerate product innovation and market access. Its collaboration with the U.S. Centers for Disease Control and Prevention (CDC), for example, has helped shape guidelines for HIV self-testing and expand community-based screening initiatives worldwide.
Under the leadership of President and CEO Douglas A. Michels, OraSure continues to invest in research and development to broaden its diagnostic pipeline, advance digital health initiatives and explore novel biomarker technologies. With a focus on improving patient access, delivering accurate results and enabling decentralized testing, the company aims to address unmet needs in infectious-disease diagnostics, genomics and therapeutic monitoring.
AI Generated. May Contain Errors.
